Literature DB >> 18333001

Sclerosing pancreatitis presenting as a periampullary tumour.

A K Sahajpal1, C M Vollmer, A Pollett, S Gallinger.   

Abstract

BACKGROUND: Sclerosing lesions of the pancreatic duct are rare and may be secondary to primary sclerosing cholangitis (PSC) or the result of a primary sclerosing process (the recently described lymphoplasmacystic sclerosing pancreatitis, LSP). Occasionally this process may present as a mass lesion. CASE OUTLINE: A 21 -year-old man presented with abdominal pain and jaundice, giving a high index of suspicion for a periampullary malignancy. There were minimal symptoms suggestive of PSC. The resected head of the pancreas demonstrated changes of chronic pancreatitis with a fibro-inflammatory process of the pancreatic duct suggesting an underlying ductal sclerosing process. DISCUSSION: Clinical presentation and imaging characteristics of PSC involving the pancreas are often misleading and may suggest a neoplasm as the underlying disorder. Conclusive diagnosis is usually not determined until after surgical intervention. Although racial differences in pancreatic duct involvement have been suggested, the underlying histopathology is the same as in PSC involving the biliary ducts.

Entities:  

Year:  2003        PMID: 18333001      PMCID: PMC2020598          DOI: 10.1080/13651820310015761

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  13 in total

Review 1.  Chronic pancreatitis and inflammatory bowel disease: true or coincidental association?

Authors:  M Barthet; P Hastier; J P Bernard; G Bordes; J Frederick; S Allio; P Mambrini; M C Saint-Paul; J P Delmont; J Salducci; J C Grimaud; J Sahel
Journal:  Am J Gastroenterol       Date:  1999-08       Impact factor: 10.864

Review 2.  Hepatobiliary manifestations of inflammatory bowel disease.

Authors:  V Raj; D R Lichtenstein
Journal:  Gastroenterol Clin North Am       Date:  1999-06       Impact factor: 3.806

Review 3.  Aetiopathogenesis of primary sclerosing cholangitis.

Authors:  S Cullen; R Chapman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-08       Impact factor: 3.043

4.  High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.

Authors:  D M Harnois; P Angulo; R A Jorgensen; N F Larusso; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

5.  Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas.

Authors:  K Kawaguchi; M Koike; K Tsuruta; A Okamoto; I Tabata; N Fujita
Journal:  Hum Pathol       Date:  1991-04       Impact factor: 3.466

6.  Recent status of primary sclerosing cholangitis in Japan.

Authors:  H Takikawa
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

7.  Autoimmune pancreatitis associated with primary sclerosing cholangitis: MR imaging findings.

Authors:  I Eerens; D Vanbeckevoort; W Vansteenbergen; L Van Hoe
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

8.  Low prevalence of alterations in the pancreatic duct system in patients with primary sclerosing cholangitis.

Authors:  U Schimanski; A Stiehl; W Stremmel; L Theilmann
Journal:  Endoscopy       Date:  1996-05       Impact factor: 10.093

9.  Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma.

Authors:  Sharon M Weber; Olcay Cubukcu-Dimopulo; J Alexander Palesty; Arief Suriawinata; David Klimstra; Murray F Brennan; Kevin Conlon
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

10.  Current concepts. Primary sclerosing cholangitis.

Authors:  N F LaRusso; R H Wiesner; J Ludwig; R L MacCarty
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.